InvestorsHub Logo
Followers 58
Posts 10041
Boards Moderated 1
Alias Born 09/21/2016

Re: ChrisMissing post# 357054

Monday, 04/11/2022 8:51:11 PM

Monday, April 11, 2022 8:51:11 PM

Post# of 458454
Very impressive language w/a theme of integrity . Classy little organization with massive potential. Nice to see they are publicly committed to the highest standards.

Excellent stuff.

A Global Burden of Disease study shows that Alzheimer's disease and other dementias are amongst the 3 most burdensome neurological disorders in the U.S. CNS disorders impact a large number of people with a variety of different cultures and personal backgrounds. From infants to the elderly, we are dedicated to addressing the devastating impact of neurological disorders through our proprietary SIGMACEPTOR™ discovery platform.

A large body of evidence indicates that sigma-1 receptors (SIGMAR1) are important drug targets for a number of neurological disorders. SIGMAR1 are enriched in the central nervous system (CNS) and are the target for the orally available ANAVEX®2-73.



https://investorshub.advfn.com/secure/post_reply.aspx?message_id=168519774
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News